Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 6Terminated 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Multiple Myeloma 61Lymphoma, Follicular 16Recurrence 13Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Large B-Cell, Diffuse 8Leukemia, Lymphocytic, Chronic, B-Cell 8Waldenstrom Macroglobulinemia 7Neoplasms 7Neoplasms, Plasma Cell 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myeloid, Acute 5Immunoblastic Lymphadenopathy 5Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Carcinoma, Non-Small-Cell Lung 4Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Erythroblastic, Acute 3Leukemia 3

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Bortezomib × Clear all
NCT00183937 2026-05-15

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

University of Southern California

Phase 2 Terminated
15 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00103376 2018-11-05

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Medical University of South Carolina

Phase 2 Terminated
23 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡